1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Neuroendocrine Tumors - Pipeline Review, H2 2016

Neuroendocrine Tumors - Pipeline Review, H2 2016

  • December 2016
  • -
  • Global Markets Direct
  • -
  • 357 pages

Neuroendocrine Tumors - Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors – Pipeline Review, H2 2016, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape.

Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.


Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Neuroendocrine Tumors – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 26, 18 and 12 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively.Neuroendocrine Tumors.

Neuroendocrine Tumors (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors (Oncology).
- The pipeline guide reviews pipeline therapeutics for Neuroendocrine Tumors (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuroendocrine Tumors (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuroendocrine Tumors (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuroendocrine Tumors (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuroendocrine Tumors (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Neuroendocrine Tumors - Pipeline Review, H2 2016
Table of Contents
Table of Contents 2
Introduction 5
Neuroendocrine Tumors Overview 6
Therapeutics Development 7
Neuroendocrine Tumors - Therapeutics under Development by Companies 9
Neuroendocrine Tumors - Therapeutics under Investigation by Universities/Institutes 12
Neuroendocrine Tumors - Pipeline Products Glance 13
Neuroendocrine Tumors - Products under Development by Companies 16
Neuroendocrine Tumors - Products under Investigation by Universities/Institutes 20
Neuroendocrine Tumors - Companies Involved in Therapeutics Development 21
Neuroendocrine Tumors - Therapeutics Assessment 62
Drug Profiles 75
Neuroendocrine Tumors - Dormant Projects 335
Neuroendocrine Tumors - Discontinued Products 337
Neuroendocrine Tumors - Product Development Milestones 338
Appendix 349

List of Tables
Number of Products under Development for Neuroendocrine Tumors, H2 2016 14
Number of Products under Development for Neuroendocrine Tumors - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Development by Companies, H2 2016 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Comparative Analysis by Late Stage Development, H2 2016 20
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Development, H2 2016 22
Products under Development by Companies, H2 2016 23
Products under Development by Companies, H2 2016 (Contd..1) 24
Products under Development by Companies, H2 2016 (Contd..2) 25
Products under Development by Companies, H2 2016 (Contd..3) 26
Products under Investigation by Universities/Institutes, H2 2016 27
Neuroendocrine Tumors - Pipeline by AbbVie Inc, H2 2016 28
Neuroendocrine Tumors - Pipeline by Advanced Accelerator Applications SA, H2 2016 29
Neuroendocrine Tumors - Pipeline by Aegis Therapeutics LLC, H2 2016 30
Neuroendocrine Tumors - Pipeline by Amgen Inc, H2 2016 31
Neuroendocrine Tumors - Pipeline by Amryt Pharma plc, H2 2016 32
Neuroendocrine Tumors - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 33
Neuroendocrine Tumors - Pipeline by Boehringer Ingelheim GmbH, H2 2016 34
Neuroendocrine Tumors - Pipeline by Bristol-Myers Squibb Company, H2 2016 35
Neuroendocrine Tumors - Pipeline by Celgene Corp, H2 2016 36
Neuroendocrine Tumors - Pipeline by Chiasma Inc, H2 2016 37
Neuroendocrine Tumors - Pipeline by Crinetics Pharmaceuticals Inc, H2 2016 38
Neuroendocrine Tumors - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 39
Neuroendocrine Tumors - Pipeline by DexTech Medical AB, H2 2016 40
Neuroendocrine Tumors - Pipeline by Eisai Co Ltd, H2 2016 41
Neuroendocrine Tumors - Pipeline by Eli Lilly and Company, H2 2016 42
Neuroendocrine Tumors - Pipeline by Esperance Pharmaceuticals Inc, H2 2016 43
Neuroendocrine Tumors - Pipeline by Exelixis Inc, H2 2016 44
Neuroendocrine Tumors - Pipeline by Foresee Pharmaceuticals LLC, H2 2016 45
Neuroendocrine Tumors - Pipeline by Hutchison MediPharma Ltd, H2 2016 46
Neuroendocrine Tumors - Pipeline by INVENT Pharmaceuticals Inc, H2 2016 47
Neuroendocrine Tumors - Pipeline by Ipsen SA, H2 2016 48
Neuroendocrine Tumors - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 49
Neuroendocrine Tumors - Pipeline by Karyopharm Therapeutics Inc, H2 2016 50
Neuroendocrine Tumors - Pipeline by Lexicon Pharmaceuticals Inc, H2 2016 51
Neuroendocrine Tumors - Pipeline by Mateon Therapeutics Inc, H2 2016 52
Neuroendocrine Tumors - Pipeline by Merck and Co Inc, H2 2016 53
Neuroendocrine Tumors - Pipeline by Midatech Pharma Plc, H2 2016 54
Neuroendocrine Tumors - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 55
Neuroendocrine Tumors - Pipeline by MolMed SpA, H2 2016 56
Neuroendocrine Tumors - Pipeline by Northwest Biotherapeutics Inc, H2 2016 57
Neuroendocrine Tumors - Pipeline by Novartis AG, H2 2016 58
Neuroendocrine Tumors - Pipeline by Peptron Inc, H2 2016 59
Neuroendocrine Tumors - Pipeline by Pfizer Inc, H2 2016 60
Neuroendocrine Tumors - Pipeline by Pharma Mar SA, H2 2016 61
Neuroendocrine Tumors - Pipeline by Progenics Pharmaceuticals Inc, H2 2016 62
Neuroendocrine Tumors - Pipeline by Provectus Biopharmaceuticals Inc, H2 2016 63
Neuroendocrine Tumors - Pipeline by Strongbridge Biopharma plc, H2 2016 64
Neuroendocrine Tumors - Pipeline by Taiwan Liposome Company Ltd, H2 2016 65
Neuroendocrine Tumors - Pipeline by Threshold Pharmaceuticals Inc, H2 2016 66
Neuroendocrine Tumors - Pipeline by Vascular Biogenics Ltd, H2 2016 67
Neuroendocrine Tumors - Pipeline by Xencor Inc, H2 2016 68
Assessment by Monotherapy Products, H2 2016 69
Number of Products by Stage and Target, H2 2016 71
Number of Products by Stage and Mechanism of Action, H2 2016 75
Number of Products by Stage and Route of Administration, H2 2016 79
Number of Products by Stage and Molecule Type, H2 2016 81
Neuroendocrine Tumors - Dormant Projects, H2 2016 342
Neuroendocrine Tumors - Dormant Projects (Contd..1), H2 2016 343
Neuroendocrine Tumors - Discontinued Products, H2 2016 344

List of Figures
Number of Products under Development for Neuroendocrine Tumors, H2 2016 14
Number of Products under Development for Neuroendocrine Tumors - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Comparative Analysis by Late Stage Development, H2 2016 20
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Products, H2 2016 22
Assessment by Monotherapy Products, H2 2016 69
Number of Products by Top 10 Targets, H2 2016 70
Number of Products by Stage and Top 10 Targets, H2 2016 70
Number of Products by Top 10 Mechanism of Actions, H2 2016 74
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 74
Number of Products by Top 10 Routes of Administration, H2 2016 78
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 78
Number of Products by Molecule Types, H2 2016 80
Number of Products by Stage and Molecule Types, H2 2016 80

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2016

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘NT-3 ...

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Review, H2 2016

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Heat Shock Protein Beta 1 (Estrogen Regulated 24 kDa Protein or Heat Shock 27 kDa Protein or Stress Responsive Protein 27 or HSP28 or HSP27 or HSPB1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.